Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

36147

Mecoprop

Name: Mecoprop
Brand: SIAL
Price: 48.7 EUR

PESTANAL^®, analytical standard

Synonym(e):

2-(4-Chlor-2-methylphenoxy)-propionsäure

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Packungsgröße	SKU	Verfügbarkeit	Preis
100 mg		Warenkorb auf Verfügbarkeit prüfen	€ 48,70

Über diesen Artikel

Empirische Formel (Hill-System):

C₁₀H₁₁ClO₃

CAS-Nummer:

93-65-2

Molekulargewicht:

214.65

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329755294

EC Number:

202-264-4

Beilstein/REAXYS Number:

6568283

MDL number:

MFCD00002648

€ 48,70

Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

grade

analytical standard

Quality Level

100

product line

PESTANAL^®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

agriculture
environmental

format

neat

SMILES string

CC(Oc1ccc(Cl)cc1C)C(O)=O

InChI

1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)

InChI key

WNTGYJSOUMFZEP-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel	45555	36850	45817
Supelco 36147 Mecoprop	Supelco 45555 MCPA	Supelco 36850 Fenoxaprop-P	Supelco 45817 Haloxyfop
format neat	format neat	format neat	format neat
technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable
product line PESTANAL^®	product line PESTANAL^®	product line PESTANAL^®	product line PESTANAL^®
grade analytical standard	grade analytical standard	grade analytical standard	grade analytical standard
shelf life limited shelf life, expiry date on the label	shelf life limited shelf life, expiry date on the label	shelf life limited shelf life, expiry date on the label	shelf life limited shelf life, expiry date on the label
application(s) agriculture environmental	application(s) agriculture environmental	application(s) agriculture environmental	application(s) agriculture environmental

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

GHS06,GHS05,GHS09

signalword

Danger

hcodes

H302,H311,H315,H318,H410

pcodes

P264 - P273 - P280 - P301 + P312 - P302 + P352 + P312 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2

Lagerklasse

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

BCCK2521

BCCB1112

BCBV9245

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with

Kohei Shitara et al.

Oncotarget, 8(45), 79546-79555 (2017-11-08)

SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and

Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.

Pablo J Maid et al.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 24(4), 177-182 (2017-12-13)

Biologic agents may induce immune responses that could impact drug action. The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.

Régis Peffault de Latour et al.

British journal of haematology, 191(3), 476-485 (2020-05-26)

Ravulizumab, a novel long-acting complement component 5 (C5) inhibitor administered every 8 weeks (q8w), was non-inferior to eculizumab for all efficacy outcomes in two randomised, open-label, phase 3 trials in C5 inhibitor-naïve (Study 301) and eculizumab-experienced (Study 302) adult patients

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.

Yutaka Osuga et al.

Obstetrics and gynecology, 133(3), 423-433 (2019-02-12)

To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events.

Kathleen Clifford et al.

Clinical journal of oncology nursing, 22(4), E103-E114 (2018-07-24)

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-expressing cells. This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell

Alle zugehörigen Dokumente anzeigen

Global Trade Item Number

SKU	GTIN
36147-100MG	04061831824230

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung